Athira Pharma announced its Phase 2 ACT-AD trial is fully enrolled and its Phase 2/3 LIFT-AD trial has reached more than half of its target number. Both studies are evaluating the safety and efficacy of ATH-1017 in people with mild to moderate Alzheimer’s disease. Eligible adults, ages 55 to 85, are still being recruited for the LIFT-AD […]

The test is an aid in differentiating sepsis from infection-negative systemic inflammation in hospitalised patients suspected of sepsis. Immunexpress has been a leader in host response sepsis diagnostics, and this second FDA clearance translates its biomarker technology to the sample-to-answer Biocartis Idylla near-patient testing platform. SeptiCyte RAPID contains all the reagents needed for quantification of […]

Rheumatology Network interviewed James Woody, MD, PhD, to understand the key findings of the Phase 2b clinical trial, “Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD).” During the study, investigators repurposed adalimumab to treat this disabling condition that causes fingers to curl irreversibly into the palm. Woody is the CEO of 180 Life Sciences. James Woody, MD, PhD: [Dupuytren’s […]